Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Diabetes (Jul 2017)

Posted by Matt Breese on Jul 17, 2017

Find me on:

According to our recent payer coverage analysis for type 2 diabetes treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: Over the past two quarters, the percentage of restricted commercial and exchange lives increased slightly. A market access snapshot of type 2 diabetes treatments shows the prevalence of utilization management for payer-controlled formularies. This requires increased attention from pharma managed markets team to understand specific brand-by-brand advantages.


MMIT data current as of Q3 2017 

Trends: Recent research reveals some prescriber trends in the market. One trend is the examination of metformin prescribing habits. Additionally, the somewhat recent approval of two type 2 diabetes treatments will introduce these products to script pads in the near future. However, some question whether the early adoption of these brands in the real-world will match expectations.

To read the full Reality Check on diabetes treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Branding & Marketing